Division of Cardiovascular Medicine

From left, Huan Tao, MD, PhD, Sean Davies, PhD, Jiansheng Huang, PhD, and MacRae Linton, MD, led the study that identified a potential new treatment for atherosclerosis.

‘Scavenger’ molecule may point to new atherosclerosis treatment

A small-molecule “scavenger” that reduces inflammation and formation of atherosclerotic plaque in blood vessels in mice potentially could lead to a new approach for treating atherosclerosis in humans, according to researchers at Vanderbilt University Medical Center.

Study suggests new threshold for diagnosing PAH

Doctors diagnosing pulmonary arterial hypertension (PAH) — elevated pulmonary pressure due to an issue in the small vessels of the lung — rely on a hemodynamic threshold set in the early 1970s to determine whether patients would be candidates for pulmonary vasodilator therapy.

Heart patient Ronnie Kreis is monitored by VHVI doctors while he’s at his home in East Tennessee.

Device allows VHVI doctors to monitor heart patients remotely

In 2018, Ronnie Kreis began to develop severe heart failure. After being hospitalized multiple times that year near his home in Oliver Springs in East Tennessee, he was told that nothing else could be done.

Soy food, metabolism and the microbiome

Consumption of soy foods may shape the microbiome and protect against hypertension only in individuals with soy-responsive microbiota, Vanderbilt researchers have discovered.

Study finds zinc doesn’t reduce mortality, other health risks, for heavy alcohol users living with HIV/AIDS

Zinc supplementation did not reduce mortality, cardiovascular risk, levels of inflammation or microbial translocation among people with heavy alcohol use living with HIV/AIDS, according to a Vanderbilt-led study.

Ventricular assist device program hits major milestone

VHVI’s cardiac surgery and heart failure teams recently celebrated a milestone — implanting the 500th adult patient with a ventricular assist device.

1 4 5 6 7 8 11